Boehringer Ingelheim gets the dirt flying on $42.5M R&D facility

Several top execs from Germany's Boehringer Ingelheim turned out at the company's U.S. headquarters in Connecticut to rub shoulders with the governor and other local officials as they touted plans for a $42.5 million research facility. Described as a safety assessment center, Boehringer is adding 63,000 square feet of space to support its R&D work in the area--a welcome development for a state that had been rattled by Pfizer's plans to slash its work in Groton.

"The fact that Boehringer Ingelheim continues to invest in its campus and create jobs is great news for Connecticut," said Governor Dannel P. Malloy, in a story by the Ridgefield Press. "This new facility expands the company's research and development capacities, and reaffirms its reputation as an innovative and forward-looking company. Boehringer Ingelheim is a valued member of the Connecticut business community and a key partner in our collective efforts to strengthen the state's bioscience industry."

Boehringer, not to be left behind in making bold pronouncements, boasted that the facility will combine "state-of-the-art technology, compliance with current good manufacturing practice and process flexibility to handle production of the many different types of APIs discovered in research," according to news reports.

- here's the story from the Ridgefield Press

Suggested Articles

Janssen’s BCMA-targeting CAR-T therapy eliminated tumors in 69% of patients with advanced multiple myeloma in a small phase 1 study.

In a study, BMS' CAR-T therapy banished tumors in more than half and shrank tumors in nearly three-quarters of relapsed blood cancer patients.

Novartis unveiled more data showing how its asthma combo QMF149 fared against the standard of care: a combination of the same types of drugs.